Vetter Pharma and Microdermics Inc. signed a strategic collaboration agreement to commercialize the latter’s hollow, metal microneedle drug delivery system, the company said Wednesday.
Vetter, a contract development and manufacturing organization (CDMO), specializes in aseptic filling and packing of compounds into syringes, vials, and cartridges. Microdermics is a Vancouver-based medical device company, which is developing a novel, hollow, metal microneedle drug.
Microneedles are innovative technology that reduces injection dosage and accelerates drug absorption in the body. As alternatives to the hypodermic needle used for over 150 years, they have formed a steadily growing market, with industry analysts estimating the market to grow to more than 480 million units by 2030.
Against this backdrop, Microdermics has developed a new commercially scalable, affordable, customizable needle to deliver vaccines and biologics, which seeks to reduce global reliance on the existing hypodermic needle. The company plans to prove the product’s safety and efficacy later this year.
The two companies will work together to overcome barriers to commercialization such as “limited investment in scalable aseptic manufacture” in late stage process development.
“We are excited to enter into this agreement with Microdermics, and we are excited by the initial experience of cooperation and entrepreneurial spirit we have established with the primary individuals at this company,” said Dr. Claus Feussner, Vetter’s Senior Vice President Development Service. “We believe that microneedles are a particularly innovative technology and may prove to be a promising future alternative for selected areas of drug delivery.”
<© Korea Biomedical Review, All rights reserved.>